DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 by Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 by Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 by Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 by Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 by Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 by Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 by Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 by Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 by Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 by Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 by Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 by Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 by Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Major UN Effort To Achieve Universal Health Coverage Taking Shape 02/04/2019 by William New NEW YORK — United Nations members and stakeholders are mobilising to bring about universal health coverage across the world with all eyes on the UN High Level Meeting on Universal Health Coverage planned for 23 September. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GARDP Set Up As Independent Legal Entity 02/04/2019 by Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 by Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 by David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> Posts navigation Older posts